Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS5554744 A
Type de publicationOctroi
Numéro de demandeUS 08/311,156
Date de publication10 sept. 1996
Date de dépôt23 sept. 1994
Date de priorité23 sept. 1994
État de paiement des fraisCaduc
Autre référence de publicationCA2200552A1, WO1996009314A2, WO1996009314A3
Numéro de publication08311156, 311156, US 5554744 A, US 5554744A, US-A-5554744, US5554744 A, US5554744A
InventeursNandkumar Bhongle, Jin-Yan Tang
Cessionnaire d'origineHybridon, Inc.
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Method for loading solid supports for nucleic acid synthesis
US 5554744 A
Résumé
New methods of loading solid supports for oligonucleotide synthesis are presented. The new methods comprise coupling a succinylated nucleoside to a solid support using diisopropylcarbodiimide (DIC) as an activator and N-hydroxybenzotriazole (HOBT) as an acid catalyst. DIC is substantially cheaper than the currently used activating agent, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (DEC). Furthermore, in the preferred embodiment, when it is used in combination with HOBT, coupling is more efficient, requiring less nucleoside to achieve the same loading densities as in the prior art. The loading process is faster than prior art methods and the overall cost savings of about 43% are realized.
Images(6)
Previous page
Next page
Revendications(27)
What is claimed is:
1. A method of loading a functionalized solid support for oligonucleotide synthesis comprising simultaneously contacting in a solvent the functionalized solid support with diisopropylcarbodiimide, a nucleoside having a 3' linker group attached, and an acid catalyst.
2. The method of claim 1 wherein the acid catalyst is N-hydroxybenzotriazole or nitrohydroxybenzotriazole, or a combination thereof.
3. The method of claim 2 wherein the solid support is CPG and less than about 3×10-3 mol of nucleoside is used per 25 g of CPG.
4. The method of claim 3 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
5. The method of claim 4 wherein the amount of N-hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 times that of the diisopropylcarbodiimide.
6. The method of claim 2 wherein the solvent comprises about 5% or less pyridine.
7. The method of claim 6 wherein the solid support is CPG and less than about 3×10-3 mol of nucleoside is used per 25 g of CPG.
8. The method of claim 7 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
9. The method of claim 8 wherein the amount of N-hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 that of the diisopropylcarbodiimide.
10. The method of claim 2 wherein the solvent contains no pyridine.
11. The method of claim 10 wherein the solid support is CPG and less than about 3×10-3 mol of nucleoside is used per 25 g of CPG.
12. The method of claim 11 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
13. The method of claim 12 wherein the amount of N-hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 that of the diisopropylcarbodiimide.
14. A method of loading a functionalized solid support for oligonucleotide synthesis comprising simultaneously contacting in a solvent a functionalized solid support having a linker moiety with diisopropylcarbodiimide, a nucleoside having a free 3' hydroxy group, and an acid catalyst.
15. The method of claim 14 wherein the acid catalyst is N-hydroxybenzotriazole or nitrohydroxybenzotriazole, or a combination thereof.
16. The method of claim 15 wherein the functionalized solid support is CPG.
17. The method of claim 16 wherein the solid support is CPG and less than about 3×10-3 mol of nucleoside is used per 25 g of CPG.
18. The method of claim 17 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
19. The method of claim 18 wherein the amount of N-hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 times that of the diisopropylcarbodiimide.
20. The method of claim 15 wherein the solvent comprises about 5% or less pyridine.
21. The method of claim 20 wherein the solid support is CPG and less than about 3×10-3 mol of nucleoside is used per 25 g of CPG.
22. The method of claim 21 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
23. The method of claim 22 wherein the amount of N-hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 that of the diisopropylcarbodiimide.
24. The method of claim 15 wherein the solvent contains no pyridine.
25. The method of claim 24 wherein the solid support is CPG and less than about 3×10-3 mol of nucleoside is used per 25 g of CPG.
26. The method of claim 25 wherein about 2 to about 3 moles of diisopropylcarbodiimide are used per mole of nucleoside.
27. The method of claim 26 wherein the amount of N-hydroxybenzotriazole or nitrohydroxybenzotriazole, or combination thereof is about 0.1 that of the diisopropylcarbodiimide.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to the field of oligonucleotide synthesis, and, more particularly, to methods of loading mononucleosides on a solid support.

2. Description of the Related Art

Since Zamecnik and Stephenson, Proc. Natl. Acad. Sci. USA 75, 280-284 (1978) first demonstrated virus replication inhibition by synthetic oligonucleotides, great interest has been generated in oligonucleotides as therapeutic agents. In recent years the development of oligonucleotides as therapeutic agents and as agents of gene expression modulation has gained great momentum. The greatest development has been in the use of so-called antisense oligonucleotides, which form Watson-Crick duplexes with target mRNAs. Agrawal, Trends in Biotechnology 10, 152-158 (1992), extensively reviews the development of antisense oligonucleotides as antiviral agents. See also Uhlmann and Peymann, Chem. Rev. 90, 543 (1990).

Various methods have been developed for the synthesis of oligonucleotides for such purposes. See generally, Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs (S. Agrawal, Ed., Humana Press, 1993); Oligonucleotides and Analogues: A Practical Approach (F. Eckstein, Ed., 1991); Uhlmann and Peyman, supra. Early synthetic approaches included phosphodiester and phosphotriester chemistries. Khorana et al., J. Molec. Biol. 72, 209 (1972) discloses phosphodiester chemistry for oligonucleotide synthesis. Reese, Tetrahedron Lett. 34, 3143-3179 (1978), discloses phosphotriester chemistry for synthesis of oligonucleotides and polynucleotides. These early approaches have largely given way to the more efficient phosphoramidite and H-phosphonate approaches to synthesis. Beaucage and Caruthers, Tetrahedron Lett. 22, 1859-1862 (1981), discloses the use of deoxynucleoside phosphoramidites in polynucleotide synthesis. Agrawal and Zamecnik, U.S. Pat. No. 5,149,798 (1992), discloses optimized synthesis of oligonucleotides by the H-phosphonate approach.

Both of these modern approaches have been used to synthesize oligonucleotides having a variety of modified internucleotide linkages. Agrawal and Goodchild, Tetrahedron Lett. 28, 3539-3542 (1987), teaches synthesis of oligonucleotide methylphosphonates using phosphoramidite chemistry. Connolly et al., Biochemistry 23, 3443 (1984), discloses synthesis of oligonucleotide phosphorothioates using phosphoramidite chemistry. Jager et al., Biochemistry 27, 7237 (1988), discloses synthesis of oligonucleotide phosphoramidates using phosphoramidite chemistry. Agrawal et al., Proc. Natl. Acad. Sci. USA 85, 7079-7083 (1988), discloses synthesis of oligonucleotide phosphoramidates and phosphorothioates using H-phosphonate chemistry.

Solid phase synthesis of oligonucleotides by the foregoing methods involves the same generalized protocol. Briefly, this approach comprises anchoring the 3'-most nucleoside to a solid support functionalized with amino and/or hydroxyl moieties and subsequently adding the additional nucleosides in stepwise fashion. Desired internucleoside linkages are formed between the 3' functional group of the incoming nucleoside and the 5' hydroxyl group of the 5'-most nucleoside of the nascent, support-bound oligonucleotide.

Oligonucleotide synthesis generally begins with coupling, or "loading," of the 3'-most nucleoside of the desired oligonucleotide to a functionalized solid phase support. A variety of solid supports and methods for their preparation are known in the art. E.g., Pon, "Solid-Phase Supports for Oligonucleotide Synthesis," in Methods in Molec. Biol., Vol. 20: Protocols for Oligonucleotides and Analogs, p. 465 (Agrawal, Ed., Humana Press, 1993). Generally, the functionalized support has a plurality of long chain alkyl amines (LCAA) on the surface that serve as sites for nucleoside coupling. Controlled pore glass (CPG) is the most widely used support. It consists of approximately 100-200 μm beads with pores ranging from a few hundred to a few thousand angstroms.

CPG supports are generally loaded by attaching a nucleoside-3'-succinate to the support through the succinyl group via an amide bond. Early efforts used dicyclohexylcarbodiimide (DCC) to activate the nucleoside-3'-succinate. Activation was accomplished by converting the nucleoside-3'-succinate into the symmetrical anhydride (Sproat and Gait, in Oligonucleotide Synthesis: a Practical Approach p. 83-115 (Gait, Ed., IRL Press, 1984)), or esterifying with p-nitrophenol (Atkinson and Smith, id. at 35-81; Koster et al., Tetrahedron 40, 103-112 (1984)) or pentachlorophenol (Gough et al, Tetrahedron Lett. 22, 4177-4180 (1981); Klerzek, Biochem. 25, 7840-7846 (1986)).

Montserrat et al., Nucleosides & Nucleotides 12, 967 (1993) reported that DCC and 1-hydoxybenzotriazole (HOBT) (used in equimolar amounts in a 14:1 dichloromethane/dimethylformamide solvent) resulted in higher loading densities than when DCC was used alone.

The use of DCC suffers from a number of disadvantages, however. First, DCC is highly toxic. Second, loading was tedious and gave only moderate yields (50-75%). Third, the coupling reactions were lengthy, requiring 3-4 d to make the activated succinates and an additional 4-7 d to couple them to the CPG. And finally, loading values were quite variable, and optimum loading of 30-40 μmol/g was not always obtained.

Pon et al., Biotechniques 6, 768-775 (1988), improved on this method by employing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (DEC). Using this reagent along with a catalytic amount of dimethylaminopyridine (DMAP) in triethylamine/pyridine, Pon et al. observed direct coupling of the nucleoside-3'-succinate to the support. DEC, a smaller, less rigid carbodiimide (compared to DCC) was found to give much better results--loadings of up to 50-60 μmol/g could be obtained in 24 hours.

In an alternative procedure, Damha et al., Nucl. Acids Res. 18, 3813-3821 (1990), showed that loading could be accomplished by succinylating the LCAA of the solid support, thereby providing a carboxylic acid functional group, followed by direct attachment of a nucleoside by esterification with DEC and DMAP in pyridine.

Tong et al., J. Org. Chem 58, 2223 (1993), followed the approach of Damha et al., supra, and compared the efficiency of DCC, DEC, and DIC in loading 3' unprotected cytidine onto a succinylated CPG support under basic conditions. The reaction was conducted in the presence of DMAP in dry pyridine. Loadings of 22 (DCC), 18 (DEC), and 30 (DIC) μmol/g were obtained.

A major drawback of the current methods for loading solid support is that the main solvent is pyridine. Pyridine is toxic, has an obnoxious odor, and, therefore, is a work place and environmental hazard. In addition, DEC is costly, particularly when used in a large, production scale syntheses. Consequently, improved methods of column loading for oligonucleotide synthesis are desirable.

SUMMARY OF THE INVENTION

The present invention comprises new and improved methods of loading nucleosides onto a solid support for solid phase oligonucleotide synthesis. The methods of the present invention provide several advantages over prior art methods. First, they are more cost efficient. Cheaper, more efficient catalysts and activators used in the present invention result in cost savings as lesser amounts of both catalyst and mononucleoside reactant are required. Savings of approximately 43% have been observed for loading densities of about 70-80 μmol/g. Second, we are able to eliminate pyridine as a solvent, which not only effects cost savings, but improves the safety of the process, both to the worker and to the environment. Concomitantly, fewer hazardous wastes are produced.

In a first aspect of the present invention, diisopropylcarbodiimide (DIC) is used as an activator in the acid catalyzed loading of succinylated mononucleoside. It has been unexpectedly found that the use of DIC in acid catalyzed loading is more effective than standard techniques using DEC; DIC is also more effective than DEC in acid catalyzed loading. DIC offers the further advantage of being cheaper per unit mass. DEC presently costs about $308/100 g while DIC costs about $97/100 g. In addition, DIC can be used in an amount that is about 20% that of DEC.

In a second aspect of the present invention, 1-hydoxybenzotriazole (HOBT) is used in combination with DIC to catalyze linkage of a mononucleoside to an activated solid support. HOBT acts more efficiently and economically than other compounds such as N-hydroxysuccinimide (NHS), paratoluenesulfonic acid (pTSA), and trifluoroacteic acid (TFA). Loading densities approaching 120 μmol/g on controlled pore glass (CPG) solid support are readily obtained. Higher loading densities are also observed on other solid supports such as the "TENTAGEL" (Rapp Polymere) and "HLP" (ABI). Nitrobenzotriazole (NBT) acts as efficiently as HOBT, but is somewhat more expensive.

In a the third aspect of the present invention, a method is presented for loading a non-linker-attached nucleoside (i.e., a nucleoside having a free 3' hydroxyl group) onto a solid support bearing a linker groug, e.g., a succinyl moiety. In this aspect of the invention, a solid support to which a linker has been attached is loaded by contacting it with a nucleoside having a free 3' hydroxyl group in the presence of DIC and HOBT.

In the fourth aspect of the present invention pyridine is eliminated as a solvent. Pyridine has generally been used in the loading process as a solvent and to dissolve and wash away all catalyst, unreacted starting materials, and reaction by-products. Because of pyridine's toxicity, its elimination from the loading process increases the safety of the process. In addition, fewer environmentally hazardous wastes are produced. We have found that acetonitrile can be used in place of pyridine without affecting loading efficiencies. Cost savings are also thereby realized.

Another benefit provided by the methods of the present invention is the ability to adjust loading densities to any desired level, up to the maximum possible empirical value obtainable under optimal conditions. This is useful because equipment limitations (and/or other factors) may restrict the degree of loading to values substantially less than the empirical maximum.

The present methods can be used to load any nucleoside onto any functionalized solid support. The nucleoside may comprise any unmodified base (e.g., A, T, C, G, or U) or modified base, and a modified or unmodified ribose moiety. Any solid support suitable for use in oligonucleotide synthesis can be used with the present methods.

The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any manner.

All patents and publications cited in this specification are hereby incorporated by reference in their entirety.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention comprises new methods for loading mononucleosides on a solid support. As used herein "loading" refers to the chemical linkage of a nucleoside (which will be the 3'-most nucleoside of the oligonucleotide to be synthesized) to a functional group on a solid support. The degree of loading is expressed in μmol monomer/g solid support. A "functional group" is a chemical moiety, such as an amino or hydroxyl moiety, capable of being joined to a nucleoside either directly or via a linker. A "functionalized support" is a support having such functional groups.

Current methods of loading solid supports are slow, often taking up to about one week to load a controlled pore glass (CPG) support, and require about 90-100 g (or about 0.15 mol) of DMT-protected succinylated monomer to load 500 g of CPG. Typical maximum loading densities are about 75 μmol/g. While loading in a 24 hour period has been reported, the loading densities are typically low. The methods presented herein substantially improve on these values. We have found that we are able to obtain loading densities in the range of 70 to 80 μmol/g using one third of the amount of DMT-protected succinylated monomer and that by increasing the amount of DMT-protected succinylated monomer, activator, and catalyst, loading densities of about 120 μmol/g are easily obtained on CPG. We have observed higher loading densities on other supports having a greater concentration of functional groups. In addition to achieving higher loading densities, the new methods are faster as well, allowing complete loading of the column (with high loading density) in just two days. Thus, use of the methods disclosed herein will substantially reduce costs and time.

The new methods disclosed herein are also significantly less hazardous for the worker and safer for the environment. Pyridine is currently used as a reaction solvent and, alone or in combination with other solvents, to wash away unreacted reactants, catalyst, and unwanted reaction by-products. We have found that the amount of pyridine can be reduced to about 5% in acetonitrile or eliminated completely. Because pyridine is toxic and has an obnoxious odor, the present methods are less hazardous than the prior art methods.

The present methods also require lesser amounts of reagents, resulting in lesser costs and amounts of waste. We have found that column loading densities in the range of about 70-80 μmol/g can be attained using less than about 3×10-3 mol of nucleoside per 25 g of CPG. Thus, the current methods provide additional cost savings by these means as well. Overall, savings of about 43% are realized with the new methods for loading densities in the range of about 70-80 μmol/g.

The present invention provides methods of loading a functionalized solid support for oligonucleoside synthesis comprising contacting the functionalized solid support with a solvent, diisopropylcarbodiimide, and a nucleoside having a 3' linker group attached at a pH of less than 7.0.

In the first embodiment of the invention, diisopropylcarbodiimide (DIC) is used as an activator for the acid catalyzed loading of nucleoside-3'-succinates. The activator forms an intermediate with the terminal carboxylic acid moiety of the nucleoside-3'-succinate, rendering it susceptible to nucleophilic attack by a support-bound amino functional group. It has been unexpectedly found that DIC in the presence of 1-hydroxybenzotirazole (HOBT) is more effective than DEC at activating the succinyl carboxylic acid moiety. Under ideal conditions, wherein the coupling of the nucleoside-3'-succinate to the solid support is 100% complete, 1 equivalent of DIC is required to couple 1 equivalent of nucleoside-3'-succinate to the support. DIC is moisture sensitive, however, and therefore, in general, more than 1 equivalent is required. This will not detract appreciably from the cost benefit of using DIC since it is substantially cheaper than DEC. We have found that about 2.5 to 3.0 eq of DIC per 1 eq of mononucleoside succinate results in excellent loading, routinely yielding loading densities of about 75 to about 85 μmol/g.

In the second embodiment of the invention, HOBT is used to catalyze DIC activated loading. Experiments using pyridine as a solvent (presented infra) demonstrate that HOBT is a more effective than other compounds such as N-hydroxysuccinimide (NHS), paratoluenesulfonic acid (pTSA), and trifluoroacetic acid (TFA). Our experiments demonstrate that the use of HOBT results in loading densities ranging from 30 to 100% greater than those attained using NHS, pTSA, and TFA. The amount of HOBT is not critical; it should be sufficient to catalyze the reaction. We have found that about 0.08 to about 0.16 g HOBT per ml DIC work exceedingly well, although lesser or greater amounts are likely to work just as well. Most preferably, a lesser amount of HOBT is used, generally about 0.08 g.

In another aspect of this embodiment, nitro-HOBT is used as a catalyst. Our experiments show that catalysis with nitro-HOBT results in essentially equivalent loading densities as compared to when HOBT is used. Nitro-HOBT is used in the amount as described above for HOBT.

The methods of the present invention can also be used to load a non-linker-attached nucleoside (i.e., a nucleoside having a free 3' hydroxyl group) onto a column bearing a linker groug, e.g., a succinyl moiety. Accordingly, in a third embodiment of the present invention, a solid support to which a linker, most preferably succinic acid, has been attached is loaded by contacting it with a nucleoside having a free 3' hydroxyl group in the presence of DIC and HOBT. The conditions for this reaction are the same as described herein for the loading of nucleosides bearing a 3' linker onto functionalized supports.

In a fourth embodiment of the present invention, methods of loading a solid support are presented in which the amount of pyridine used as the reaction solvent and wash solvent is substantially reduced or eliminated. We have found that pyridine need not be the main solvent in the loading reaction. Any solvent that dissolves the reactants but does not react itself can be used. We have found that both acetonitrile and dichloromethane are suitable solvents. Acetonitrile is the most preferred solvent. In one aspect of this embodiment, a mixture of pyridine with acetonitrile and/or dichloromethane is used as the primary solvent for loading nucleosides. A small amount of pyridine (e.g., about 5%) may be used to ensure a minimal amount of detritylation, but is not required. Accordingly, in another aspect of this embodiment, no pyridine is used. Because of the reduced costs, in the most preferred embodiment the solvent is acetonitrile with very little (e.g., 5% or less) or no pyridine.

The present invention can be used with any functionalized solid support. A number of such supports are known in the art. E.g., Pon in Methods in Molec. Biol., supra. We demonstrate below that both "TENTAGEL S" (Rapp Polymere, T ubingen, Germany)(a support in which polyethyleneglycol spacers are grafted on a gel-type support) and HLP (ABI, Foster City, Calif.) (a PEG-Polystyrene support) can be loaded with the current methods to extremely high densities. CPG is the most preferred support for DNA synthesis.

While the results presented below were obtained using succinylated thymidine monomer, those skilled in the art will appreciate that any suitably protected nucleoside monomer (naturally occurring or modified) can be used with the present methods. Dimer blocks and other multinucleoside synthons can also be loaded according to the methods of the present invention. In addition, although succinic acid is the preferred linker, any suitable linker can be used. Such a linker will preferably have a free carboxyl group that a support-bound amino group can attack to form an amide bond, thereby binding the linker and its attached nucleoside to the support. Examples of alternative linkers are disclosed by Pon in Methods in Molec. Biol., supra.

The following Examples are intended for illustrative purposes and are not intended, nor should they be construed, as limiting the invention in any way.

EXAMPLES Example 1 Standard Method of Loading of DMT-dT-Succinic Acid on Controlled Pore Glass

500 g of CPG (Schott, Hozheim, Germany) (particle size: 100-130 μm; pore size: D50 : 41.6 nm), 6.1 g of dimethylamino pyridine (Aldrich, Milwaukee, Wis.), 50 g of triethylamine (Aldrich), and 100 g of ethyl-3-(3-dimethylamino propyl)carbodiimide (DEC, mol. wt. 191.7) (Sigma, St. Louis, Mo.) were placed in a 5 l Schott bottle and hand shaken for 20 minutes. 60 g of DMT-dT-succinic acid (Monomer Sciences, Huntsville, Ala.) was added and the bottle capped and shaken in an orbital shaker at 160 rpm for 18 hours.

A small analytical sample of the resin was withdrawn from the Schott bottle, successively washed with pyridine (3×5 ml) (Baxter, Muskegon, Mich.), methanol (3×5 ml) (Baxter), and methylene chloride (3×5 ml) (EM Science, Cincinnati, Ohio) successively, and dried in vacuo.

Approximately 20 mg of dry resin was weighed, 200 μl perchloric acid/ethanol (6:4) was added, and the resulting solution diluted to 100 ml with methylene chloride. The absorbance was measured at 498 nm. The same procedure was repeated on a second analytical sample and the average loading value calculated using Beer's law with a molar absorption coefficient of 70 l/(mol cm) for DMT. A loading value of 66.7 μmol/g was obtained.

An additional 20.0 g of DMT-dT-succinic acid was added to the Schott bottle and the mixture shaken for 18 hours at ambient temperature. Another analytical sample was removed and worked-up as described above. The absorbance of the sample was measured and a loading value of 66.5 μmol/g obtained.

Another 20.0 g of DMT-dT-succinic acid was added to the Schott bottle and the mixture shaken for 18 hours at ambient temperature. A third analytical sample was removed and worked-up as described above. The absorbance of the sample was measured and a loading value of 69.6 μmol/g obtained.

The mixture remaining in the Schott bottle was filtered and the resin washed with pyridine (3×1 l). The dry solid was transferred to a Schott bottle and Cap A (1.0 l of acetic anhydride in tetrahydrofuran) (Cruachem, Linvingstone, United Kingdom) and Cap B (1.5 l of N-methylimidzole, pyridine in tetrahydrofuran) (Millipore, Bedford, Mass.) were added. The mixture was shaken for 18 hours at ambient temperature. The solid (CPG-T) was filtered and successively washed with methanol (3×1 l) and methylene chloride (3×1 l) and dried in vacuo to yield 502.5 g. The resin was subjected to the same procedure described above for each of the small samples. A loading value of 71.4 μmol/g was obtained.

Example 2 New Method of Loading DMT-dT-Succinic Acid on Controlled Pore Glass

250.0 g of CPG (Schott), 0.8 g of hydroxybenzotriazole (mol. wt. 135.13) (Aldrich), and 10 ml of 1,3-diisopropylcarbodiimide (DIC, mol. wt. 126.20, density=0.806 g/ml) (Aldrich) were mixed with 50 ml of pyridine (Baxter) and 1 l of acetonitrile (Baxter) in a 2 l Schott bottle and shaken for 20 minutes. 15 g of DMT-T-succinic acid (mol. wt. 644) (Monomer Sciences) were added, the bottle stoppered and shaken in an orbital shaker at a rate of 180 rpm for 16 hours.

A small analytical sample of the resin was withdrawn from the Schott bottle and washed with 5% pyridine in acetonitrile (3×5 ml), methanol (3×5 ml), and methylene chloride (3×5 ml) successively and dried under a stream of in vacuo.

Approximately 20 mg of the dry resin were weighed and 200 ml perchloric acid/ethanol (6:4) added. The solution was diluted to 70 ml with methylene chloride and the absorbance measured at 498 nm. The entire procedure was repeated and the average value of the absorbencies used to calculate the loading. The loading was calculated as above. An average loading value of 78.0 μmol/g was obtained.

The remaining solution in the Schott bottle was filtered and washed with 5% pyridine in acetonitrile (3×500 ml). Dry solid was transferred to a Schott bottle and Cap A (500 ml) and Cap B (750 ml) (Cap A and Cap B were as described above) were added and the mixture shaken for 16 hours at ambient temperature. The solid (CPG-T) was filtered, washed successively with methanol (3×500 ml) and then methylene chloride (3×500 ml), and dried in vacuo to yield 250 g of CPG-T. The loading value, 78 μmol/g, was calculated as described above.

This entire procedure was repeated, substituting varying amounts of the reactants and using several catalysts and supports. The results are present in Table 1.

From the foregoing it will be appreciated that although specific embodiments of the present invention have been described herein for the purposes of illustration, various modification may be made without deviating from the spirit or scope of the invention.

                                  TABLE 1__________________________________________________________________________    CPG  Schott       Pyridine            CH.sub.3 CN                  DMT-T-SA.sup.c                         DIC DEC HOBT NBT                                         NHS pTSA                                                 TFA LoadExpt #    (g)  Lot #       (ml) (ml)  (g)    (ml)                             (g) (g)  (g)                                         (g) (g) (g) (μmol/g)__________________________________________________________________________ 1  500  100004       2500 --    90     --  100 --   -- --  --  --  73 2  25.0  "    125  --    2.6    6.2 --  --   -- --  --  --  31.7 3  "  "    "    --    "      "   --  1.0  -- --  --  --  81.5 4  "  "    "    --    "      "   --  --   -- 1.0 --  --  62.8 5  "  "    "    --    "      "   --  --   -- --  1.0 --  24.1 6  "  "    "    --    "      "   --  --   -- --  --  1.0 36.3 7  "  "    12   113   "      "   --  1.0  -- --  --  --  112.5 8  "  "    6    115   "      "   --  "    -- --  --  --  114.6 9  "  "    "    "     1.3    "   --  "    -- --  --  --  67.210  "  "    "    "     2.6    "   --  0.50 -- --  --  --  119.511  250  "    50   1000  15.0   20  --  1.60 -- --  --  --  77.912  25 1100002       5    1000  1.5    2   --  0.16 -- --  --  --  86.013  25 "    5    100.sup.d                  1.5    2   --  "    -- --  --  --  80.514  250  "    50   1000  15.0   10  --  0.80 -- --  --  --  7815  25 "    0    100   1.5    1   --  0.08 -- --  --  --  80.616  25 "    5    100   1.5    1   --  --   0.08                                         --  --  --  76.317  50.sup.a  --   10   300   6.0    8   --  0.64 -- --  --  --  14518  5.9.sup.b  --   5    50    1.0    2   --  0.16 -- --  --  --  187__________________________________________________________________________ .sup.a "TENTAGEL" (Rapp Polymere) .sup.b HLP, ABI .sup.c DMTT- Succinic Acid .sup.d CH.sub.2 Cl.sub.2
Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US5149798 *6 avr. 198922 sept. 1992Worcester Foundation For Experimental BiologyProcess for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
Citations hors brevets
Référence
1 *Agrawal and Goodchild, Tetrahedron Lett. 28, 3539 3542 (1987).
2Agrawal and Goodchild, Tetrahedron Lett. 28, 3539-3542 (1987).
3 *Agrawal et al., Proc. Natl. Acad. Sci. USA 85, 7079 7083 (1988).
4Agrawal et al., Proc. Natl. Acad. Sci. USA 85, 7079-7083 (1988).
5 *Agrawal et al., Trends in Biotech. 10, 152 158 (1992).
6Agrawal et al., Trends in Biotech. 10, 152-158 (1992).
7 *Beaucage and Caruthers, Tetrahedron Lett. 22, 1859 1862 (1981).
8Beaucage and Caruthers, Tetrahedron Lett. 22, 1859-1862 (1981).
9 *Connolly et al., Biochemistry 23, 3443 (1984).
10 *Damha et al., Nucleic Acid Res. 18, 3813 3821 (1990).
11Damha et al., Nucleic Acid Res. 18, 3813-3821 (1990).
12 *Gough et al., Tetrahedron Lett. 22, 4177 4180 (1981).
13Gough et al., Tetrahedron Lett. 22, 4177-4180 (1981).
14 *Jager et al., Biochemistry 27, 7237 (1988).
15 *Khorana et al., J. Molec. Biol. 72, 209 (1972).
16 *Kierzek, Biochemistry 25, 7840 7846 (1986).
17Kierzek, Biochemistry 25, 7840-7846 (1986).
18 *Koster et al., Tetrahedron 40, 103 112 (1984).
19Koster et al., Tetrahedron 40, 103-112 (1984).
20 *Montserrat et al., Nucleosides & Nucleotides 12, 967 (1993).
21 *Pon et al., Biotechniques 6, 768 775 (1988).
22Pon et al., Biotechniques 6, 768-775 (1988).
23Pon, "Solid Phase Supports for Oligonucleotide Synthesis," Methods in Molec. Biol., vol. 20: Protocols for Oligonucleotides and Analogs, p. 465 (Agrawal, Ed. Humana Press (1993)).
24 *Pon, Solid Phase Supports for Oligonucleotide Synthesis, Methods in Molec. Biol., vol. 20: Protocols for Oligonucleotides and Analogs, p. 465 (Agrawal, Ed. Humana Press (1993)).
25 *Reese, Tetrahedron Lett. 34, 3143 3179 (1978).
26Reese, Tetrahedron Lett. 34, 3143-3179 (1978).
27 *See generally, Methods in Molecular Biology, vol. 20: Protocols for Oligonucleotides and Analogs (S. Agrawal, Ed. Humana Press (1993)).
28 *See generally, Oligonucleotides and Analogues: A Practical Approach (F. Eckstein, Ed. (1991)).
29 *Sproat and Gait, in Oligonucleotide Synthesis: A Practical Approach, pp. 83 115 (Gait, Ed., IRL Press, 1984).
30Sproat and Gait, in Oligonucleotide Synthesis: A Practical Approach, pp. 83-115 (Gait, Ed., IRL Press, 1984).
31 *Tong et al., J. Org. Chem. 58, 2223 2231 (1993).
32Tong et al., J. Org. Chem. 58, 2223-2231 (1993).
33 *Uhlmann and Peyman, Chem. Rev. 90, 543 (1990).
34 *Zamecnik and Stephenson, Proc. Natl. Acad. Sci. USA 75, 280 284 (1978).
35Zamecnik and Stephenson, Proc. Natl. Acad. Sci. USA 75, 280-284 (1978).
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US6048695 *4 mai 199811 avr. 2000Baylor College Of MedicineChemically modified nucleic acids and methods for coupling nucleic acids to solid support
US733547015 oct. 200226 févr. 2008Perkinelmer, Las, Inc.Compilations of nucleic acids and arrays and methods of using them
US742543116 août 200616 sept. 2008President And Fellows Of Harvard CollegePolony fluorescent in situ sequencing beads
US743934617 mai 200421 oct. 2008Perkinelmer Las Inc.Nucleic acids arrays and methods of use therefor
US7695910 *28 août 200613 avr. 2010Samsung Electronics Co., Ltd.Method for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group
US852468031 août 20093 sept. 2013Applied Biosystems, LlcHigh potency siRNAS for reducing the expression of target genes
US85867273 févr. 201219 nov. 2013Mirna Therapeutics, Inc.Synthetic mimics of miR-34
US863724622 févr. 201128 janv. 2014Dana-Farber Cancer Institute, Inc.BRAF mutations conferring resistance to BRAF inhibitors
US881582120 oct. 201126 août 2014Life Technologies CorporationDouble-stranded oligonucleotides
US908478110 déc. 200921 juil. 2015Novartis AgMEK mutations conferring resistance to MEK inhibitors
US92791444 déc. 20138 mars 2016Dana-Farber Cancer Institute, Inc.Screening method for BRAF inhibitors
US937152615 nov. 201321 juin 2016Mirna Therapeutics, Inc.Synthetic mimics of miR-34
US947608918 oct. 201225 oct. 2016President And Fellows Of Harvard CollegeMethods of making oligonucleotide probes
US951248113 sept. 20106 déc. 2016The Regents Of The University Of Colorado, A Body CorporatePolymorphisms in the PDE3A gene
US959225029 juil. 201414 mars 2017Life Technologies CorporationDouble-stranded oligonucleotides
US20030003496 *26 juil. 20022 janv. 2003Baylor College Medicine, A Texas CorporationNovel compositions and methods for array-based nucleic acid hybridization
US20030124542 *8 févr. 20023 juil. 2003Spectral Genomics, Inc.Methods for mapping the chromosomal loci of genes expressed by a cell
US20030124599 *14 nov. 20023 juil. 2003Shiping ChenBiochemical analysis system with combinatorial chemistry applications
US20040009493 *15 oct. 200215 janv. 2004Spectral Genomics, Inc.Compilations of nucleic acids and arrays and methods of using them
US20050009051 *22 avr. 200413 janv. 2005Board Of Regents, The University Of TexasDiagnosis of mould infection
US20060257902 *27 mars 200616 nov. 2006Ambion, Inc.Methods and compositions for depleting abundant RNA transcripts
US20060275787 *27 déc. 20057 déc. 2006Allan BradleyCompositions and methods for array-based genomic nucleic acid analysis of biological molecules
US20070020676 *28 août 200625 janv. 2007Nam HuhMethod for manufacturing hydrogel biochip by using star-like polyethylene glycol derivative having epoxy group
US20070087362 *16 août 200619 avr. 2007President And Fellows Of Harvard CollegePolony fluorescent in situ sequencing beads
US20100047876 *31 juil. 200925 févr. 2010President And Fellows Of Harvard CollegeHierarchical assembly of polynucleotides
US20110045080 *24 mars 201024 févr. 2011William Marsh Rice UniversitySingle-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
EP2065466A231 mai 20053 juin 2009Asuragen, Inc.Methods and compositions involving MicroRNA
EP2241330A113 févr. 200420 oct. 2010The Curators Of The University Of MissouriContraceptive methods and compositions related to proteasomal interference
EP2246444A114 sept. 20053 nov. 2010The Regents of the University of Colorado, A Body CorporateMethod for treatment with bucindolol based on genetic targeting
EP2281886A114 nov. 20059 févr. 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2281887A114 nov. 20059 févr. 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2281888A114 nov. 20059 févr. 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2281889A114 nov. 20059 févr. 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2284265A114 nov. 200516 févr. 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2287303A114 nov. 200523 févr. 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2290066A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290067A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290068A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290069A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290070A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290071A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290072A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290073A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290074A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290075A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2290076A231 mai 20052 mars 2011Asuragen, Inc.Methods and compositions involving microRNA
EP2292755A114 nov. 20059 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2292756A114 nov. 20059 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2298893A114 nov. 200523 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2298894A114 nov. 200523 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2302051A114 nov. 200530 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2302052A114 nov. 200530 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2302053A114 nov. 200530 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2302054A114 nov. 200530 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2302055A114 nov. 200530 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2302056A114 nov. 200530 mars 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2314688A114 nov. 200527 avr. 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2322616A114 nov. 200518 mai 2011Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2471921A131 mai 20054 juil. 2012Asuragen, Inc.Methods and compositions involving microRNA
EP2471922A131 mai 20054 juil. 2012Asuragen, Inc.Methods and compositions involving microRNA
EP2471923A131 mai 20054 juil. 2012Asuragen, Inc.Methods and compositions involving microRNA
EP2471924A131 mai 20054 juil. 2012Asuragen, INC.Methods and compositions involving microRNA
EP2474616A131 mai 200511 juil. 2012Asuragen, Inc.Methods and compositions involving microRNA
EP2474617A111 janv. 201111 juil. 2012InteRNA Technologies BVMir for treating neo-angiogenesis
EP2487240A119 sept. 200715 août 2012Asuragen, Inc.Micrornas differentially expressed in pancreatic diseases and uses thereof
EP2772550A117 nov. 20113 sept. 2014Asuragen, Inc.MiRNAs as biomarkers for distinguishing benign from malignant thyroid neoplasms
EP2789689A129 juin 201015 oct. 2014Luminex CorporationChimeric primers with hairpin conformations and methods of using same
EP2808389A114 nov. 20053 déc. 2014Asuragen, Inc.Methods and compositions involving MIRNA and MIRNA inhibitor molecules
EP2808390A114 nov. 20053 déc. 2014Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2944649A19 janv. 200918 nov. 2015Research Development FoundationVaccines and diagnostics for the ehrlichioses
EP2990487A18 mai 20092 mars 2016Asuragen, INC.Compositions and methods related to mirna modulation of neovascularization or angiogenesis
EP3028699A122 févr. 20118 juin 2016Dana-Farber Cancer Institute, Inc.Braf mutations conferring resistance to braf inhibitors
EP3178932A13 févr. 201214 juin 2017Mirna Therapeutics, Inc.Synthetic mimics of mir-34
EP3214174A14 mars 20116 sept. 2017InteRNA Technologies B.V.A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
WO2006110314A227 mars 200619 oct. 2006Ambion, Inc.Methods and compositions for depleting abundant rna transcripts
WO2008036776A219 sept. 200727 mars 2008Asuragen, Inc.Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2009094647A226 janv. 200930 juil. 2009Introgen Therapeutics, Inc.P53 biomarkers
WO2010054328A29 nov. 200914 mai 2010Research Development FoundationCompositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2010068738A110 déc. 200917 juin 2010Dana-Farber Cancer Institute, Inc.Mek mutations conferring resistance to mek inhibitors
WO2010084488A119 janv. 201029 juil. 2010Ramot At Tel-Aviv University Ltd.Mir-21 promoter driven targeted cancer therapy
WO2011025905A127 août 20103 mars 2011Research Development FoundationUrocortin 2 analogs and uses thereof
WO2011079273A223 déc. 201030 juin 2011Arca Biopharma, Inc.Methods and compositions for cardiovascular diseases and conditions
WO2011099664A112 févr. 201018 août 2011M&D.Inc.Probe for hpv genotype diagnosis and analysis method thereof
WO2011106298A122 févr. 20111 sept. 2011Dana-Farber Cancer Institute, Inc.Braf mutations conferring resistance to braf inhibitors
WO2011108930A14 mars 20119 sept. 2011Interna Technologies BvA MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
WO2011128886A110 mars 201120 oct. 2011Ramot At Tel Aviv University Ltd.A micro-rna for cancer diagnosis, prognosis and therapy
WO2011156588A19 juin 201115 déc. 2011Dana-Farber Cancer Institute, Inc.A mek 1 mutation conferring resistance to raf and mek inhibitors
WO2012005572A11 juil. 201112 janv. 2012Interna Technologies BvMirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012068400A217 nov. 201124 mai 2012Asuragen, Inc.Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms
WO2012096573A110 janv. 201219 juil. 2012Interna Technologies B.V.Mirna for treating diseases and conditions associated with neo-angiogenesis
WO2012106586A13 févr. 20129 août 2012Mirna Therapeutics, Inc.Synthetic mimics of mir-124
WO2012106591A13 févr. 20129 août 2012Mirna Therapeutics, Inc.Synthetic mimics of mir-34
WO2013037065A113 sept. 201221 mars 2013Ottawa Hospital Research InstituteMicrorna inhibitors
WO2013040251A213 sept. 201221 mars 2013Asurgen, Inc.Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
WO2013055995A212 oct. 201218 avr. 2013President And Fellows Of Harvard CollegeSequencing by structure assembly
WO2013063519A126 oct. 20122 mai 2013Asuragen, Inc.Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
WO2013095132A120 déc. 201227 juin 2013Interna Technologies B.V.Mirna for treating head and neck cancer
WO2013184754A25 juin 201312 déc. 2013President And Fellows Of Harvard CollegeSpatial sequencing of nucleic acids using dna origami probes
WO2014014991A217 juil. 201323 janv. 2014President And Fellows Of Harvard CollegeMethods of storing information using nucleic acids
WO2014055117A113 mars 201310 avr. 2014Asuragen, Inc.Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
WO2014072357A16 nov. 201315 mai 2014Interna Technologies B.V.Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
Classifications
Classification aux États-Unis536/25.3
Classification internationaleC07H21/00
Classification coopérativeC07H21/00
Classification européenneC07H21/00
Événements juridiques
DateCodeÉvénementDescription
13 févr. 1995ASAssignment
Owner name: HYBRIDON, INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BHONGLE, NANDKUMAR;TANG, JIN YAN;REEL/FRAME:007336/0591
Effective date: 19950119
29 janv. 1998ASAssignment
Owner name: SILICON VALLEY BANK, MASSACHUSETTS
Free format text: SECURITY INTEREST;ASSIGNOR:HYBRIDON, INC.;REEL/FRAME:008933/0844
Effective date: 19980116
28 févr. 2000FPAYFee payment
Year of fee payment: 4
27 oct. 2000ASAssignment
Owner name: BOSTON BIOSYSTEMS, INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HYBRIDON, INC.;REEL/FRAME:011284/0457
Effective date: 20000919
30 janv. 2001ASAssignment
Owner name: BOSTON BIOSYSTEMS, INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HYBRIDON, INC.;REEL/FRAME:011742/0986
Effective date: 20000919
Owner name: AVECIA BIOTECHNOLOGY INC., MASSACHUSETTS
Free format text: RE-RECORD TO CORRECT THE RECORDATION OF 05-07-01 TO 01-30-01, PREVIOUSLY RECORDED ON REEL 011796, FRAME 0219.;ASSIGNOR:BOSTON BIOSYSTEMS, INC.;REEL/FRAME:012435/0445
Effective date: 19970629
7 mai 2001ASAssignment
Owner name: AVECIA BIOTECHNOLOGY INC., MASSACHUSETTS
Free format text: CHANGE OF NAME;ASSIGNOR:BOSTON BIOSYSTEMS, INC.;REEL/FRAME:011796/0219
Effective date: 20010118
26 oct. 2001ASAssignment
Owner name: AVECIA BIOTECHNOLOGY INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HYBRIDON, INC.;REEL/FRAME:012391/0898
Effective date: 20000919
4 févr. 2004FPAYFee payment
Year of fee payment: 8
1 sept. 2004ASAssignment
Owner name: J.P. MORGAN EUROPE LIMITED, AS SECURITY AGENT, UNI
Free format text: SECURITY AGREEMENT;ASSIGNOR:AVECIA BIOTECHNOLOGY INC.;REEL/FRAME:015056/0902
Effective date: 20040826
9 févr. 2006ASAssignment
Owner name: NEORESINS INC., MASSACHUSETTS
Free format text: RELEASE OF GUARANTEE AND COLLATERAL AGREEMENT, ACKNOWLEDGEMENT AND CONFIRMATION OF GUARANTEE AND COLLATERAL AGREEMENT AND SECURITY INTEREST;ASSIGNOR:J.P. MORGAN EUROPE LIMITED (FORMERLY KNOWN AS CHASE MANHATTAN INTERNATIONAL LIMITED);REEL/FRAME:017145/0397
Effective date: 20060206
Owner name: AVECIA INVESTMENTS LIMITED, UNITED KINGDOM
Free format text: RELEASE OF GUARANTEE AND COLLATERAL AGREEMENT, ACKNOWLEDGEMENT AND CONFIRMATION OF GUARANTEE AND COLLATERAL AGREEMENT AND SECURITY INTEREST;ASSIGNOR:J.P. MORGAN EUROPE LIMITED (FORMERLY KNOWN AS CHASE MANHATTAN INTERNATIONAL LIMITED);REEL/FRAME:017145/0397
Effective date: 20060206
Owner name: AVECIA HOLDINGS INC., DELAWARE
Free format text: RELEASE OF GUARANTEE AND COLLATERAL AGREEMENT, ACKNOWLEDGEMENT AND CONFIRMATION OF GUARANTEE AND COLLATERAL AGREEMENT AND SECURITY INTEREST;ASSIGNOR:J.P. MORGAN EUROPE LIMITED (FORMERLY KNOWN AS CHASE MANHATTAN INTERNATIONAL LIMITED);REEL/FRAME:017145/0397
Effective date: 20060206
Owner name: AVECIA INC., DELAWARE
Free format text: RELEASE OF GUARANTEE AND COLLATERAL AGREEMENT, ACKNOWLEDGEMENT AND CONFIRMATION OF GUARANTEE AND COLLATERAL AGREEMENT AND SECURITY INTEREST;ASSIGNOR:J.P. MORGAN EUROPE LIMITED (FORMERLY KNOWN AS CHASE MANHATTAN INTERNATIONAL LIMITED);REEL/FRAME:017145/0397
Effective date: 20060206
Owner name: AVECIA BIOTECHNOLOGY INC., MASSACHUSETTS
Free format text: RELEASE OF GUARANTEE AND COLLATERAL AGREEMENT, ACKNOWLEDGEMENT AND CONFIRMATION OF GUARANTEE AND COLLATERAL AGREEMENT AND SECURITY INTEREST;ASSIGNOR:J.P. MORGAN EUROPE LIMITED (FORMERLY KNOWN AS CHASE MANHATTAN INTERNATIONAL LIMITED);REEL/FRAME:017145/0397
Effective date: 20060206
Owner name: AVECIA IPC INC., DELAWARE
Free format text: RELEASE OF GUARANTEE AND COLLATERAL AGREEMENT, ACKNOWLEDGEMENT AND CONFIRMATION OF GUARANTEE AND COLLATERAL AGREEMENT AND SECURITY INTEREST;ASSIGNOR:J.P. MORGAN EUROPE LIMITED (FORMERLY KNOWN AS CHASE MANHATTAN INTERNATIONAL LIMITED);REEL/FRAME:017145/0397
Effective date: 20060206
17 mars 2008REMIMaintenance fee reminder mailed
10 sept. 2008LAPSLapse for failure to pay maintenance fees
28 oct. 2008FPExpired due to failure to pay maintenance fee
Effective date: 20080910